<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="4871">
  <stage>Registered</stage>
  <submitdate>7/07/2014</submitdate>
  <approvaldate>7/07/2014</approvaldate>
  <nctid>NCT02191150</nctid>
  <trial_identification>
    <studytitle>Study of Haemodialysis Patients Switching From Aranesp to Biosimilar</studytitle>
    <scientifictitle>Retrospective Study of Stable Haemodialysis Patients Switched From Darbepoetin Alfa to Epoetin Alfa Biosimilar</scientifictitle>
    <utrn />
    <trialacronym>SHADE</trialacronym>
    <secondaryid>20130300</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Anaemia</healthcondition>
  </conditions>
  <interventions>
    <interventions>Cohort 1 - Patients with CKD

</interventions>
    <comparator />
    <control />
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Haemoglobin Concentration - Mean haemoglobin concentration over time</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>ESA Doses - Doses of ESA over time.</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dose ratio - Dose ratio between the start of the post-switch observation period and pre-switch</outcome>
      <timepoint>Start post-switch (weeks 1-4) and pre-switch (weeks -4--1)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Dose ratio - Dose ratio between the end of the post-switch observation period and pre-switch</outcome>
      <timepoint>Between end of post-switch (weeks 23-26) and pre-switch (weeks -4--1)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemoglobin excursions - Haemoglobin excursions (&lt;10/dL and &gt;12g/dL)</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Haemglobin within range - Haemoglobin in the range 10-12g/dL over time</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>TSAT, ferritin and albumin values - TSAT, ferritin and albumin over time</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Iron Use - Iron use (dose/route) over time</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Red cell transfusions (including number of units transfused) - Red cell transfusions (including number of units transfused)</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Hospitalisations (including primary cause) - Hospitalisations (including primary cause)</outcome>
      <timepoint>Duration of observation period -52 weeks</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Inclusion Criteria

          -  Patients =18 years of age

          -  Patients with CKD on haemodialysis and fulfilling the following:

               -  Received HD for at least 26 weeks prior to switching from treatment with
                  darbepoetin alfa to treatment with an EMA/TGA-approved epoetin alfa biosimilar

               -  Received darbepoetin alfa treatment i.v. for at least 26 weeks immediately prior
                  to switching to an EMA/TGA-approved epoetin alfa biosimilar (breaks due to
                  treatment being intentionally withheld are permitted)

               -  Switched from darbepoetin alfa treatment to an EMA/TGA-approved epoetin alfa
                  biosimilar at least 26 weeks prior to enrolment

               -  Received at least one dose of an EMA/TGA-approved epoetin alfa biosimilar after
                  switching from darbepoetin alfa treatment

          -  Mean monthly Hb 10-12g/dL in the 12 weeks prior to switch

          -  Stable darbepoetin alfa dose (i.e. no more than one increment or decrement of PFS) in
             the 12 weeks prior to switch

          -  Patient or patient's legally acceptable representative has provided informed consent,
             if applicable according to local requirements</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage />
    <inclusivemaxagetype>No limit</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Treatment with an ESA other than darbepoetin alfa during the 12 weeks prior to switch
             to biosimilar

          -  More than 14 days' cumulative treatment with short-acting ESA during weeks 26-13 prior
             to switch to biosimilar

          -  Subject received chemotherapy or major surgery during the 26 weeks prior to switch to
             biosimilar

          -  Subject was enrolled in an interventional device or drug study at any time during the
             52-week data observation period or within 30 days prior to commencement of the data
             observation period.</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Observational</studytype>
    <purpose />
    <allocation />
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing>Retrospective</timing>
  </trial_design>
  <recruitment>
    <phase>Not Applicable</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2014</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>272</actualsamplesize>
    <recruitmentstatus>Completed</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/05/2015</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>QLD</recruitmentstate>
    <hospital>Research Site - Herston</hospital>
    <hospital>Research Site - Nambour</hospital>
    <hospital>Research Site - Woolloongabba</hospital>
    <postcode>4029 - Herston</postcode>
    <postcode>4560 - Nambour</postcode>
    <postcode>4102 - Woolloongabba</postcode>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Burgas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lemgo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Lich</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Minden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Egaleo, Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Egaleo</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Kallithea, Athens</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Larissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Greece</country>
      <state>Patra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milazzo ME</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Pisa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Chojnice</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Gdansk</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Krakow</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Lublin</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Poznan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Poland</country>
      <state>Rybnik</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Andalucía</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Spain</country>
      <state>Castilla León</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Amgen</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>The study will obtain data to show insight into clinical outcomes of patients switching from
      Darbepoetin Alfa to a epoetin alfa biosimilar.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02191150</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>MD</name>
      <address>Amgen</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>